...Definitive Management of Oral Mucositis
Home About Oral Mucositis About ProThelial™ FAQs Patients Healthcare Professionals Contact us
 
Press Releases
Articles
Upcoming Events
 

News 

Articles

Polymerized Cross-linked Sucralfate Paste Should Acquire a Recommendation 
for Use in the MASCC/ISOO Mucositis Guidelines through the Adaptation of a 
New Category of Level of Evidence

Abstract
The level of evidence categories used for guideline recommendations of the MASCC/ISOO 
(Multi-national Association of Support in Cancer Care and International Society of Oral Oncology)
should be expanded to include as Level IA evidence case reports that show Glasziou treatment 
effects, that is treatment effects with rate ratios beyond 1,100%. This category expansion of 
evidence can be used by the Panel on guidelines to elevate obscure, but versatile interventions 
to mainstream attention, thereby exposing practitioners to novel therapeutic tools that alter 
the course of disease and perhaps save lives...[More]


Novel 2-3 day Simultaneous Reversal of Oral and Alimentary Mucositis using 
Polymerized Cross Linked Sucralfate 
Abstract
The quest to optimize cancer treatments and to extend cancer survival is consistently 
thwarted by an unavoidable but expected consequence – mucositis of the oral and 
gastrointestinal tract. Prior to market approval our Translational Medicine Research 
Center clinically tested polymerized cross-linked sucralfate (PCLS) on a cancer treatment 
patient who underwent 6 weeks chemo-radiation for squamous cell carcinoma of head and 
neck (SCCHN)...[More]


Asessment of Oral Mucositis in Adult and Pediatric Oncology Patients 
Abstract
Oral mucositis is a frequent side effect of cancer treatment and can lead to delayed treatment, 
reduced treatment dosage, altered nutrition, dehydration, infections, xerostomia, pain, and 
higher healthcare costs. Mucositis is defined as “inflammatory lesions of the oral and/or 
gastrointestinal tract caused by high-dose cancer therapies....[More]

The Challenges of Oral Mucositis and Its Therapy
In many regards, oral mucositis has long been an ignored toxicity in those patients who 
undergo anticancer therapies, including those who receive high-dose therapy with an 
autologous or allogeneic stem cell transplant. Until recently, this has been largely 
due to the lack of effective therapy to prevent or treat oral mucositis, other than 
topical rinses, anesthetics, or systemic opioids. [MORE]

Effect of Granulocyte-Macrophage Colony-Stimulating Factor on Oral 
Mucositis in Head and Neck Cancer Patients After Cisplatin, Fluorouracil,
and Leucovorin Chemotherapy
Despite high response rates, oral musositis is one of the dose-limiting toxicities of 
cisplatin, fluorouracil (5-FU), and leucovorin (PFL) chemotherapy in squamous cell 
carcinoma of the head and neck region. 1-4 Oral mucositis (grade a 2) was reported in up 
to 90% of cases after PFL chemotherapy. Oral mucositis may be intensively painful and may 
lead to weight loss from odynodysphagia. [MORE]

Development and Validation of a Patient-Reported Oral Mucositis 
Symptom (PROMS) Scale
'Oral mucositis, which is characterized by painful erythematous, erosive and
ulcerative lesions of the oral mucosa, is a common complication of many cancer treatments,
including myeloablative forms of bone marrow transplant therapy. Between 30% and
69% of patients undergoing bone marrow transplantation experience oral mucositis,
and nearly all such patients experience some form of oral complications [MORE]

Patient-reported Measurements of Oral Mucositis in Head and Neck 
Cancer Patients Treated With Radiotherapy With or Without Chemotherapy
Mucositis is a painful and debilitating side effect of radiation therapy (RT) for head and neck
cancers and is exacerbated by concomitant chemotherapy. Mucositis lesions, characterized by 
ulceration and pseudomembranous formations, occur in the oral cavity, oropharynx, and hypopharynx. 
Oral mucositis is a consistent finding in patients treated for oral cavity and/or oropharynx tumors, 
but the reported incidence and severity are less among individuals treated for larynx or hypopharynx 
cancers. [MORE]

Risk Outcomes and costs of radiation-induced oral mucositis
among patients with head and neck malignancies
Oral mucositis (OM) is a common and dose-limiting toxicity of radiotherapy (RT) among 
patients with head and neck primary cancers (1). In recent years, altered fractionation and 
the addition of chemotherapy have improved local control and survival in this population at the 
expense of an increased incidence of OM (2). This trend is clinically significant because OM leads 
to a reduction of quality of life through its association with increased pain, declining performance 
status, inability to eat, and need for feeding tubes [MORE]






          Copyright© Mueller Medical International LLC 2014. All rights reserved.